GlaxoSmithKline PLC Director/PDMR Shareholding (4548I)
April 14 2022 - 9:23AM
UK Regulatory
TIDMGSK
RNS Number : 4548I
GlaxoSmithKline PLC
14 April 2022
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Dr H Barron
==== ======================================== ====================================================
b) Position/status Chief Scientific Officer and President,
R&D
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 7
April 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.7026 2,382.518
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-04-12
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr J Ford
==== ======================================== ====================================================
b) Position/status SVP and Group General Counsel, Legal and
Compliance
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 7
April 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.7026 463.284
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-04-12
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr B McNamara
==== ======================================== ====================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 7
April 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.7026 1,524.579
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-04-12
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Shobie Ramakrishnan
==== ======================================== ====================================================
b) Position/status Chief Digital and Technology Officer
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 7
April 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.7026 82.814
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-04-12
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHXZLFFLZLLBBF
(END) Dow Jones Newswires
April 14, 2022 09:23 ET (13:23 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024